PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Tesamorelin — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Tesamorelin is a growth hormone-releasing factor analogue based on the full GHRH(1-44) sequence. · pmid:20554713

History

A pooled analysis of two phase 3 trials in 806 HIV patients on antiretroviral therapy with excess abdominal fat found visceral fat reduced after 26 weeks of daily tesamorelin compared with placebo. · pmid:20554713

Identity

PubChem CID 16137828: Tesamorelin, C221H366N72O67S, 5136 g/mol. · pubchem:16137828

CAS registry number 218949-48-5. · pubchem:16137828

Where the evidence actually sits

Established100%

Proportion of the 1 claim about Tesamorelin standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. (2010) · established20102010

1 resolved citation, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Tesamorelin yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. · pmid 20554713 · 2010
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

1 resolved citation, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.